Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
please.....
I feel like i could get some more in under .45 tomorrow around close
think we will go any lower than .4 from here forward?
interested to see how it holds up to Friday sell-off. Im all in on a few other positions so I can't add anything here. Just hopin to get out of this 40% hole sooner than later.
must be something in the air, as the three positions i have that I'm extremely underwater on all had 20%+ gains today
I still fell you are completely overlooking the difference between selling a product and making a product. If this company had sales of any significant quantity lined up, why wouldn't they be sharing that information? The only plausible reason in my mind would be to extend the time someone can load up on shares, but it would have to be company related. Thoughts?
What did he say that wasn't true?
I would think, as a public company, that if there were orders just waiting to be filled, they would have been sharing this information all along. Don't you think?
Mass production for whom?
in my opinion, on a penny-stock with very minimal visibility, it doesn't hold the significance it might with a stronger business.
As Expected: Amedica Granted 180-Day Extension by NASDAQ to Regain Compliance With Minimum Bid Price Rule
SALT LAKE CITY, Aug. 20, 2015 (GLOBE NEWSWIRE) -- Amedica Corporation (Nasdaq:AMDA), an innovative biomaterial company which develops and manufactures silicon nitride as a platform for biomedical applications, announced today that on August 19, 2015, it received a notification from the NASDAQ Stock Market indicating that the Company will have an additional 180-day grace period, until February 15, 2016 to regain compliance with NASDAQ’s $1.00 minimum bid requirement. The notification indicated that the Company did not regain compliance during the initial 180-day grace period provided under the rule. In accordance with NASDAQ Marketplace Rule 5810(c)(3)(A), the Company is eligible for the additional grace period because it meets the initial listing requirements for the NASDAQ Capital Market except for the bid price and provided written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary.
The NASDAQ letter does not impact Amedica’s listing on The NASDAQ Capital Market at this time and Amedica’s common stock will continue to trade under its current symbol "AMDA" during the additional 180-day compliance period.
The Company can regain compliance by maintaining a minimum closing bid price of $1.00 per share for 10 consecutive business days. If Amedica does not meet the minimum bid requirement during the 180-day grace period, NASDAQ will provide written notification to the Company that its common stock will be subject to delisting. At that time, the Company can ask NASDAQ for a hearing to present a plan to regain compliance.
About Amedica Corporation
Amedica is focused on the development and application of medical-grade silicon nitride ceramics. Amedica markets spinal fusion products and is developing a new generation of wear- and corrosion-resistant implant components for hip and knee arthroplasty. The Company manufactures its products in its ISO 13485 certified manufacturing facility and, through its partnership with Kyocera, the world's largest ceramic manufacturer. Amedica's spine products are FDA-cleared, CE-marked, and are currently marketed in the U.S. and select markets in Europe and South America through its distributor network and its growing OEM partnerships.
For more information on Amedica or its silicon nitride material platform, please visit www.amedica.com.
Forward-Looking Statements
This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties. For example, there can be no assurance that we will be able to maintain our listing on any NASDAQ market. Other factors that could cause actual results to differ materially from those contemplated within this press release can also be found in Amedica's Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 24, 2015, and in Amedica's other filings with the SEC. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.
Contact:
Mike Houston
VP, Commercialization & Communications
801-839-3534
mhouston@amedica.com
Source: Amedica Corporation
no one gonna sticky q2?
Oh im well aware, i owned an rx-7 for a short period...blew the apex seals and didnt have the cash to rebuild. On the motorcycles, I think a lot of those two-strokes weren't true rotary engines because only the intake was a rotary disk. I remember reading that years ago so whether or not its fact I dont know. This design is really nothing like the Wankel design that has been the basis for modern rotary engine design since the 50's and it differs drastically from rotary disks. I agree with you though, the design looks very nice and I think it has a ton of promise. I just think there's too much history around rotary engines and longevity issues for the world to jump ship on proven technology without a little bit of solid real world use data.
Not real positive what I confirmed, but you're welcome.
I sure do hope you're correct.
I will actually be glad to and unfortunately I have to deal with legal and lawyers more often than i'd like.
I could probably, and I say probably because I haven't thrown anything in a minute, hit two GE 15MW recovery boiler turbines from my office with a baseball. I've purchased one of them. I've spent more money with Siemens in the past 6 months than Coates will probably be able to profit in the next decade, so spare me the 'i've got a bigger pencil than you' shenanigans because its not the case here. Outside of actual work where ive spent more time arguing over 2 words in a collection of 10,000 than i'd ever like to admit, i've spent 100+ hours of my life in t's & c's training and i personally sign 10-20 NDA's a year with companies coming into our facility to data gather for the purpose of us trialing their equipment/product and I actually just had to sign one going into another facility two weeks ago for a tour. That NDA means nothing other than "I can sue you if you share information". If that's what you're using to say that they have an official agreement, then sure I guess they do have an official agreement. However, for me personally as an investor, i care about agreements that generate cash and this isn't there yet. I'm not saying its not coming...which is why i bought shares of this today, i think if things go well this could do very well.
I've never said that they aren't dealing with each other, but rather my point is that I don't believe this to some imminent business deal within the next 6-12 months. This engine will not sell in mass until its reliability is proven in working conditions over years. People will try it, sure, but it takes a long time for a product such as this to actually take hold. This concept has been discussed since the 50's, Coates are just the first to make an actual functioning product and I hope they are extremely successful and I hope they start working with companies outside of cummins. When I was talking about this engine with my GM about a week ago, he actually got a little pissed off because he remembered back in the late 80's while working on a motorcycle engine discussing this exact style design with a buddy of his and saying at the time he could maybe make a million dollars off of something like that.
Realistically, if ol' Zamarra is sitting at their next meeting and this rebuild has a failure or doesn't perform to promise, how long do you think that will set back this "relationship"?
If a company buys a Siemens drive system.....they don't have to get permission from Siemens to publish "we bought a Siemens Drive system". It's a factual statement that doesn't have any connotation involved. In this case, if Cummins legal was involved, which i doubt they were, there is 0 legal reason for them to say 'dont put our name on your PR'.
Cummins power systems is a distribution company for cummins products in a certain region and the GM of Sales visited the coates facility along with the manager of sales and marketing. I meet with GM's of sales several times a month and we trial several hundred thousand dollars worth of new technology products on the vendors dime every year. Maybe 5% turn into real purchases. To me, what further lowers the severity of that meeting is that there were no procurement related individuals present, which shows that there currently isn't a serious intent for cummins to spend large $ with Coates. It really means nothing long-term until we see the PR that states clearly that they have a signed agreement. Definitely interested to see how the next rebuild goes. Keep in mind though, one fatal issue and the interest from Cummins will disappear fast.
Don't think im bashing either please, just sharing my thoughts. I actually bought a few shares today.
As a fella that does industrial procurement for a living, I feel that even if this 250KW test (which is a pretty small generator) does very well and performs well, if Cummins tried to offer this style motor as part of any package they were quoting to me, I would require several examples of this technology running 5-10 years in a a similar environment before I'd even read through the proposal. Rotary Engines were all the rage until they ran them for 5 years. Cummins isnt ignorant to this. This is a decade long process to generate solid consistent sales if it is indeed successful.
I see the greatest thing since pockets two or three times a week. Really revolutionary stuff on all sorts of different machinery and products, but selling that stuff is a completely different ballgame. Someone has to put their profits on the line to test your product and in industries like utilities/oil/paper you are talking 10's of thousands of dollars an hour in profit that will be lost if your new product doesn't function as expected. If Cummins were to come out a month from now and say that the retrofit was a huge success and they loved the product, Cummins wouldn't be able to sell those engines in any serious quantity for quite some time.
I say all that only reading into this company over the past few days. I'm sure there is a lot of information that I do not know about and that's fine. Just sharing my thoughts on the little I know and basically just saying that it looks fruitful, but this is an long-term investment for sure.
needs some sort of exposure. 45k isnt gonna do it.
August 5, 2015 – InspireMD, Inc. (NYSE MKT: NSPR) a leader in stent embolic prevention systems (“EPS”) and thrombus management technologies, today announced that it has entered into a partnership with Penumbra, Inc. to distribute its carotid CGuardTM EPS through their direct commercialization team. Penumbra is a leading interventional technology company that develops and markets innovative medical devices to the neurovascular and peripheral vascular communities around the world.
InspireMD has aggressively been pursuing a strategy in treating carotid artery disease and other neurovascular applications for its proprietary MicroNetTM technology. Clinical trials of the CGuardTM system, including the recent CARENET and PARADIGM studies, have continued to support the benefits of the MicroNetTM enhanced CGuardTM system resulting in increased commercial adoption throughout the European market.
Penumbra has a direct and distributor sales organization in all markets where the CGuardTM system is commercially available. Penumbra’s neurovascular product portfolio includes medical devices for ischemic stroke and brain aneurysms, as well as peripheral vascular products that include products for embolization and thrombectomy. Penumbra has approximately 1,000 global employees with direct sales operations in North America, Europe, and Australia. Penumbra sells through distributors in Asia and select other international markets.
Alan Milinazzo, CEO of InspireMD, commented, “We are excited to partner with a leading global organization such as Penumbra. The Penumbra commercial organization is a well-respected, strong and growing team of experienced professionals that will help communicate the benefits of our proprietary CGuardTM EPS to all specialists that manage carotid artery disease.” Milinazzo continued, “We are confident that the Penumbra team will successfully commercialize CGuardTM over the next several months. Penumbra’s customers have already started placing the CGuardTM device and are anxious to discuss additional possible uses of the MicroNetTM technology in the neurovascular space.”
In addition, Jim Pray, President, International of Penumbra, stated, “The Penumbra team is looking forward to offering the CGuardTM to our customers. The CGuardTM carotid system from InspireMD is unique and addresses many limitations of existing carotid stents. The CGuardTM offers an unmatched ability to protect against plaque protrusion and prevent embolic events. The InspireMD team has done a remarkable job getting this breakthrough technology to market and our customers are looking forward to incorporating it into their practices. We are fortunate to be able to partner with InspireMD.”
CGuardTM EPS is CE Mark approved. CGuardTM EPS, however, is not approved for sales in the U.S. by the U.S. Food and Drug Administration at this time.
About Penumbra, Inc.
Penumbra, Inc. (www.penumbrainc.com) is a global interventional therapies company that designs, develops, manufactures and markets innovative medical devices. The company has a broad portfolio of products that address challenging medical conditions and significant clinical need across two major markets, neuro and peripheral vascular. Penumbra has approximately 1,000 employees and sells its products to hospitals primarily through its direct sales organization in the U.S., most of Europe, Canada and Australia, and through distributors in select international markets.
About InspireMD, Inc.
InspireMD (www.inspiremd.com) seeks to utilize its proprietary MGuard™ with MicroNetTM technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.
InspireMD intends to pursue applications of this MicroNet technology in coronary, carotid (CGuardTM), neurovascular, and peripheral artery procedures. InspireMD’s common stock is quoted on the NYSE MKT under the ticker symbol NSPR.
Forward-looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Investor Contacts:
InspireMD, Inc.
Craig Shore
Chief Financial Officer
Phone: 1-888-776-6804
Email: craigs@inspiremd.com
PCG Advisory
Vivian Cervantes
Investor Relations
Phone: (212) 554-5482
Penumbra, Inc
Penumbra Media Relations:
Merryman Communications
Betsy Merryman
310-560-8176
betsy@merrymancommunications.com
If you do it 5 days a week you're bound to be right at some point
congrats. I tried to put in an order on the ask with 30 seconds left in the day and it didn't get filled:/
posting your opinion is awesome, that's the point of a forum. Posting your repetitive opinion 50 times in a two hour period imo should be against forum rules, as it takes away from the integrity of the forum
If it drops under .25 I will just purchase more as it drops. I'm not selling jack for 6 months and i'll re-evaluate at that time. Short term really isn't a concern of mine on this company.
I can only hope! i can add to these .25's :) If you're trying to make a quick buck, maybe you are right.....if you are an investor, just owning shares anywhere in the area will make you money.
tried to set a buy this morning at .5 and im still a day out waiting on funds:(
Holding. And will hold for 6 months.
Obviously because it was overvalued on initial hype. How does that affect whether or not it will grow long term? Its held around its current PPS for over 30 days it's not like its bleeding everyday.
another 500% and I can break even:)
if you say it everyday for the next 6 months, it may eventually come true:)
right behind ya, sellin at a 54% loss before it gets to 60%
Well hopefully it will get back into the 20's so I can load up some more:)
i'm in at the low 20's so I will just hold and load up when it bottoms out. I think technically the FDA could approve in 3 weeks if they see fit, so i'd rather not miss the train
2nd quarter 10Q probably wont get released until September or October if that past two delays serve as any indicator. Am I incorrect here?
advice on a good entry point?
In 2015, the last three times the %b has been where its at currently, we've had two very hard spikes over a few days and 1 more gradual growth period over several weeks in May. I think its very favorable that we are in for a good spike here in the coming days.
based on what exactly?
my e-trade is showing 9 stocks in my watchlist with 0 activity. very odd
its been in their business plan for 6+ months.....
I'm in at .24 and im sittin through the summer. It may fall in the meantime....although more than likely not to my in point. This will be worth well over $1 by the end of summer.
Then you'd be surprised how many business owners worth millions run their company's out of domestic homes....I have two of them in my family and personally know several others. Distributing requires nothing but a warehouse and a van.